Curium Pharma (PRIVATE.CURIUM)

Overall impact
B (77)

Commentary

Curium Pharma is a strong overall performer. With a 'B' rating of 77.0 for overall impact (91st percentile compared to all companies), Curium Pharma ranks 133rd out of 670 industry peers, behind Cell Source, Amgen, Pulmatrix and 129 others, and ahead of Allena Pharmaceuticals, Pluristem Therapeutics, Kadmon and 534 others. On top material causes for Curium Pharma's industry (Biotechnology), Curium Pharma performs well in Accountable Institutions (95.0 score), Child and Maternal Health (86.7), Accountable Institutions (92.6) and 47 other causes where it received an 'A' score and performs poorly in Reduced Use of tobacco (37.5 score) and Reduced Use of tobacco (37.5).
Screens
Fur
Impact
Cause PRIVATE.CURIUM
Peer rank
Overall impact

Log in to view this information

Screens
Fur
Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
5,000
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
France
Share classes
PRIVATE.CURIUM
Curium Pharma
Description
Manufacturer of radiopharmaceutical products designed to enhance the lives of people with cancer. The company specializes in the production and supply of radioactive tracers used in nuclear medicine, enabling doctors to accurately diagnose and treat cancer with effective treatment and proven patient outcomes.
Material causes
Ethos considers the following causes material for Curium Pharma, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.